Aldeyra Therapeutics Faces Class Action for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics (NASDAQ:ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between November 3, 2023, and March 16, 2026, with a deadline to contact the firm by May 29, 2026, for participation.
- False Statement Allegations: The complaint alleges that Aldeyra made false and misleading statements regarding the clinical trial results of its reproxalap drug candidate, with inconsistencies rendering the company's positive assertions unreliable, thus making its public statements materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Aldeyra, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could lead to stock price declines and erode investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected investors to reach out to discuss their rights, demonstrating the firm's commitment to protecting shareholder interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.590
Low
9.00
Averages
9.50
High
10.00
Current: 1.590
Low
9.00
Averages
9.50
High
10.00
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aldeyra Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between November 3, 2023, and March 16, 2026, with a deadline to contact the firm by May 29, 2026, for participation.
- False Statements Allegation: The complaint alleges that Aldeyra made misleading statements regarding the clinical trial results of its reproxalap drug candidate, which were inconsistent, rendering the company's positive assertions unreliable and leading to investor losses when the truth emerged.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to reach out before class certification to ensure their rights are protected and to avoid being absent class members.
- Market Reaction Impact: As the market becomes aware of Aldeyra's misleading statements, investor losses are expected to increase, highlighting significant deficiencies in the company's transparency and compliance, which could have long-term repercussions on its future financing and market trust.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, that May 29 is the crucial deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, misleading investors about the company's business and prospects, which ultimately led to financial losses, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and experience in handling similar cases.
See More
Aldeyra Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Aldeyra Therapeutics and certain officers, aiming to recover damages for investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, indicating strong investor concern over potential fraud.
- Detailed Allegations: The complaint alleges that defendants made false or misleading statements throughout the class period and failed to disclose inconsistencies in clinical trial results, rendering any purported positive findings unreliable and severely undermining investor confidence in the company's prospects.
- Urgent Action for Investors: Affected investors have until May 29, 2026, to request to be appointed as lead plaintiff, creating a sense of urgency for investors to act quickly to potentially share in any recovery from the lawsuit.
- Law Firm's Reputation: Bronstein, Gewirtz & Grossman, LLC is a well-regarded firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, showcasing its expertise and successful track record in handling such cases.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, minimizing financial burdens for investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding inconsistent clinical trial results for its drug candidate reproxalap, leading to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
See More
Reminder of Aldeyra Therapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which reduces financial risk for investors and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, leading to investor losses when the true information became public, highlighting significant deficiencies in the company's transparency and disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
Aldeyra Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics for violations of securities laws, involving securities transactions from November 3, 2023, to March 16, 2026, with a deadline to contact the firm by May 29, 2026, for participation.
- False Statement Allegations: The complaint alleges that Aldeyra made misleading statements regarding its reproxalap drug candidate, as clinical trial results showed inconsistencies, rendering the company's positive claims unreliable and misleading throughout the class period.
- Investor Losses: Investors suffered damages when the market learned the truth about Aldeyra, indicating significant deficiencies in the company's disclosure practices that could adversely affect its future stock price and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests.
See More
Aldeyra Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between November 3, 2023, and March 16, 2026, with a deadline to contact the firm by May 29, 2026, for participation.
- False Statements Allegation: The complaint alleges that Aldeyra made misleading statements regarding the clinical trial results of its reproxalap drug candidate, which were inconsistent, rendering the company's positive assertions unreliable and leading to investor losses when the truth emerged.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to reach out before class certification to ensure their rights are protected and to avoid being absent class members.
- Market Reaction Impact: As the market becomes aware of Aldeyra's misleading statements, investor losses are expected to increase, highlighting significant deficiencies in the company's transparency and compliance, which could have long-term repercussions on its future financing and market trust.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, that May 29 is the crucial deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, misleading investors about the company's business and prospects, which ultimately led to financial losses, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and experience in handling similar cases.
See More
Aldeyra Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Aldeyra Therapeutics and certain officers, aiming to recover damages for investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, indicating strong investor concern over potential fraud.
- Detailed Allegations: The complaint alleges that defendants made false or misleading statements throughout the class period and failed to disclose inconsistencies in clinical trial results, rendering any purported positive findings unreliable and severely undermining investor confidence in the company's prospects.
- Urgent Action for Investors: Affected investors have until May 29, 2026, to request to be appointed as lead plaintiff, creating a sense of urgency for investors to act quickly to potentially share in any recovery from the lawsuit.
- Law Firm's Reputation: Bronstein, Gewirtz & Grossman, LLC is a well-regarded firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, showcasing its expertise and successful track record in handling such cases.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, minimizing financial burdens for investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding inconsistent clinical trial results for its drug candidate reproxalap, leading to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
See More
Reminder of Aldeyra Therapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which reduces financial risk for investors and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, leading to investor losses when the true information became public, highlighting significant deficiencies in the company's transparency and disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
Aldeyra Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics for violations of securities laws, involving securities transactions from November 3, 2023, to March 16, 2026, with a deadline to contact the firm by May 29, 2026, for participation.
- False Statement Allegations: The complaint alleges that Aldeyra made misleading statements regarding its reproxalap drug candidate, as clinical trial results showed inconsistencies, rendering the company's positive claims unreliable and misleading throughout the class period.
- Investor Losses: Investors suffered damages when the market learned the truth about Aldeyra, indicating significant deficiencies in the company's disclosure practices that could adversely affect its future stock price and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests.
See More
